Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 16/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 16/20 | 0.45 |
| ▸ | APLNR | P35414 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148565 | 0.93 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1 | |
| SCHEMBL1148685 | 0.79 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1 | |
| SCHEMBL1147983 | 0.78 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1 | |
| SCHEMBL1147829 | 0.78 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1 | |
| SCHEMBL1148633 | 0.75 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1 | |
| SCHEMBL1148518 | 0.73 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1 | |
| SCHEMBL17166183 | 0.73 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1 | |
| SCHEMBL3106385 | 0.71 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1 | |
| SCHEMBL14618263 | 0.71 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1 | |
| SCHEMBL1148571 | 0.71 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160000756-A1 | IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-07 | — | — | US | disclosed |
| US-9156794-B2 | Imidazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-8629285-B2 | Imidazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20070087998-A1 | Imidazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000756-A1 | IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885APLNR 4747/4885 |
| US-20070087998-A1 | Imidazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885APLNR 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.